keyword
MENU ▼
Read by QxMD icon Read
search

interferon therapy in hepatitis C

keyword
https://www.readbyqxmd.com/read/29773440/case-report-identification-of-recombinant-hcv-genotype-1b-2b-by-viral-sequencing-in-two-patients-with-treatment-failure-who-responded-to-re-treatment-with-sofosbuvir-and-daclatasvir
#1
Luis Antonio Uribe-Noguez, Alicia Ocaña-Mondragón, José Antonio Mata-Marín, Allison Cázares-Cortázar, Rosa María Ribas-Aparicio, María Elena Gómez-Torres, Jesus Gaytán-Martínez, María de la Luz Martínez-Rodríguez
Hepatitis C virus (HCV) infection is a global health problem. HCV has been classified into seven genotypes and >67 subtypes. Genotyping is necessary to enable selection of appropriate treatments. The commercial molecular techniques currently used do not identify some HCV subtypes, mixed infections and recombinant forms. In this study, the core-E1 and NS5B regions were sequenced and phylogenetically analysed to identify infections by HCV recombinant genotype 1b-2b in two patients who had initially been diagnosed with HCV genotype 2 infection by reverse hybridization with a Versant HCV Genotype 2...
May 15, 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/29768546/first-wave-protease-inhibitors-for-hepatitis-c-genotype-1-treatment-a-real-life-experience-in-brazilian-patients
#2
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli
INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center...
March 2018: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/29766002/influence-of-vitamin-d-receptor-gene-polymorphisms-on-response-to-pegylated-interferon-in-chronic-hepatitis-b-egyptian-patients
#3
Gomaa Mostafa-Hedeab, Dina Sabry, Ghada Mostafa Abdelaziz, Manal Ewaiss, Nagla Adli, Wael Fathy
Background: We explored the effect of vitamin D receptor gene ( VDR ) polymorphisms in response to PEG-IFN treatment in Egyptian chronic hepatitis B (CHB) patients. Methods: Two hundred hepatitis B virus (HBV) patients (42.3±10.7 years) on PEG-IFN α-2a (180 µg /kg for 48 weeks) and one hundred control subjects (37.3 ±12 years) were enrolled in the study. Vitamin D levels and hepatitis B surface antigen (HBsAg) expression were assessed by ELISA. VDR polymorphisms FokI T>C (rs 10735810), BsmI A>G (rs 1544410), ApaI (rs7975253), and TaqI C>T (rs 731236), were genotyped using real-time PCR...
April 2018: Reports of Biochemistry & Molecular Biology
https://www.readbyqxmd.com/read/29765541/the-effect-of-antiviral-therapy-on-serum-lipid-profiles-in-chronic-hepatitis-c
#4
Batbold Batsaikhan, Ching-I Huang, Ming-Lun Yeh, Chung-Feng Huang, Nei-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Jin-Ching Lee, Chia-Yen Dai
Background: Low lipid profile is associated with hepatitis C virus (HCV) infection. Chronic HCV infection is the main cause of liver injury and serum lipid levels during antiviral treatment. We aimed to evaluate the effect of antiviral treatment on the change of lipid profiles during HCV treatment. Methods: Total 863 patients who complete the interferon-based therapy in Kaohsiung Medical University Hospital were included in this study. The lipid profile measured and evaluated in baseline and after 6 months of the treatment...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29765256/grazoprevir-elbasvir-for-the-treatment-of-adults-with-chronic-hepatitis-c-a-short-review-on-the-clinical-evidence-and-place-in-therapy
#5
REVIEW
Nimisha Sulejmani, Syed-Mohammed Jafri
Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection...
2018: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29761292/-chronic-hepatitis-b-and-d-delta-current-and-future-treatments
#6
REVIEW
N Wortmann, C Höner Zu Siederdissen, M Cornberg
BACKGROUND: Worldwide, hepatitis B virus (HBV) infection is among the 30 leading causes of death, despite effective vaccination and therapeutic options. Chronic hepatitis delta (coinfection with hepatitis D virus) leads to a rapid disease progression. AIMS: Based on current international guidelines and studies, an overview about present and future therapeutic options for chronic hepatitis B and delta is provided. RESULTS: Therapy with nucleoside or nucleotide analogues leads to nearly complete HBV DNA suppression, which is associated with regression of liver fibrosis and a lower risk for the development of hepatocellular carcinoma...
May 14, 2018: Der Internist
https://www.readbyqxmd.com/read/29755758/autoantibodies-in-chronic-hepatitis-c-virus-infection-impact-on-clinical-outcomes-and-extrahepatic-manifestations
#7
Andrew J Gilman, An K Le, Changqing Zhao, Joseph Hoang, Lee A Yasukawa, Susan C Weber, John M Vierling, Mindie H Nguyen
Goals: To examine the role that autoantibodies (auto-abs) play in chronic hepatitis C virus (HCV) regarding demographics, presence of extrahepatic manifestations and long-term outcomes in a large US cohort. Background: Auto-abs have been reported to be prevalent in patients with chronic HCV infection, but data on the natural history of these patients are limited. Study: The study included 1556 consecutive patients with HCV without concurrent HIV and/or HBV who had testing for antinuclear antibody (ANA), antimitochondrial antibody (AMA), antismooth muscle antibody (ASMA) and/or antiliver kidney microsomal antibody (LKM)...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29750037/simple-score-to-predict-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-c-patients-with-advanced-fibrosis-after-pegylated-interferon-and-ribavirin-therapy
#8
Ching-Chih Hu, Cheng-Hao Weng, Liang-Che Chang, Chih-Lang Lin, Yen-Ting Chen, Ching-Fang Hu, Man-Chin Hua, Li-Wei Chen, Rong-Nan Chien
Purpose: Eradication of chronic hepatitis C virus (HCV) after interferon-based therapy and its association with the reduction of risk of hepatocellular carcinoma (HCC) in HCV-infected patients with advanced fibrosis is controversial. The study is aimed to develop a simple scoring model for HCC prediction among advanced fibrotic chronic hepatitis C (CHC) patients after pegylated interferon (pegIFN) and ribavirin (RBV) therapy. Patients and methods: We enrolled 271 biopsy-proven CHC patients with advanced fibrosis between 2003 and 2016, and divided them into non-HCC (n=211) and HCC (n=60) groups...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29744922/substitutions-in-interferon-sensitivity-determining-region-and-hepatocarcinogenesis-after-hepatitis-c-virus-eradication
#9
Satoshi Yasuda, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi, Hidenori Toyoda, Takashi Kumada, Yoshiki Hirooka, Hidemi Goto
BACKGROUND AND AIM: Amino acid substitutions in the interferon sensitivity determining region (ISDR) within the NS5A region are known to be associated with responsiveness to interferon (IFN) based therapy. Additionally, previous studies reported that the ISDR was related to the development of hepatocellular carcinoma (HCC) in patients infected with hepatitis C virus (HCV). However, the association between substitutions in the ISDR and the development of HCC in patients who achieved sustained virological response (SVR) is unclear...
May 9, 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29743015/mortality-trends-among-people-with-hepatitis-b-and-c-a-population-based-linkage-study-1993-2012
#10
Maryam Alavi, Jason Grebely, Behzad Hajarizadeh, Janaki Amin, Sarah Larney, Matthew G Law, Jacob George, Louisa Degenhardt, Gregory J Dore
BACKGROUND: This study evaluated cause-specific mortality trends including liver-related mortality among people with a hepatitis B virus (HBV) and hepatitis C virus (HCV) notification in New South Wales, Australia. METHODS: Notifications 1993-2012 were linked to cause-specific mortality records 1993-2013. RESULTS: Among 57,929 and 92,474 people with a HBV and HCV notification, 4.8% and 10.0% died since 1997. In early 2010s, 28% and 33% of HBV and HCV deaths were liver-related, 28% and 17% were cancer-related (excluding liver cancer), and 5% and 15% were drug-related, respectively...
May 9, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29740665/real-world-virological-efficacy-and-safety-of-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-virus-genotype-1-infection-in-japan
#11
Hidenori Toyoda, Masanori Atsukawa, Koichi Takaguchi, Tomonori Senoh, Kojiro Michitaka, Atsushi Hiraoka, Shinichi Fujioka, Chisa Kondo, Tomomi Okubo, Haruki Uojima, Toshifumi Tada, Hirohito Yoneyama, Tsunamasa Watanabe, Toru Asano, Toru Ishikawa, Hideyuki Tamai, Hiroshi Abe, Keizo Kato, Kunihiko Tsuji, Chikara Ogawa, Noritomo Shimada, Etsuko Iio, Akihiro Deguchi, Ei Itobayashi, Shigeru Mikami, Akio Moriya, Hironao Okubo, Joji Tani, Akihito Tsubota, Yasuhito Tanaka, Tsutomu Masaki, Katsuhiko Iwakiri, Takashi Kumada
BACKGROUND: The real-world virological efficacy and safety of an interferon (IFN)-free direct-acting antiviral (DAA) therapy with elbasvir (EBR) and grazoprevir (GZR) were evaluated in Japanese patients chronically infected with hepatitis C virus (HCV) genotype 1. METHODS: The rate of sustained virologic response (SVR) and safety were analyzed in patients who started the EBR/GZR regimen between November 2016 and July 2017. SVR rates were compared based on patient baseline characteristics...
May 8, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29740402/characterization-of-hepatitis-c-virus-ires-quasispecies-from-the-individual-to-the-pool
#12
Václav Vopálenský, Anas Khawaja, Luděk Rožnovský, Jakub Mrázek, Tomáš Mašek, Martin Pospíšek
Hepatitis C virus (HCV) is a single-stranded positive-sense RNA virus from the genus Hepacivirus . The viral genomic +RNA is 9.6 kb long and contains highly structured 5' and 3' untranslated regions (UTRs) and codes for a single large polyprotein, which is co- and post-translationally processed by viral and cellular proteases into at least 11 different polypeptides. Most of the 5' UTR and an initial part of the polyprotein gene are occupied by an internal ribosome entry site (IRES), which mediates cap-independent translation of the viral proteins and allows the virus to overcome cellular antiviral defense based on the overall reduction of the cap-dependent translation initiation...
2018: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29739095/distribution-of-il28b-rs12979860-and-rs8099917-genotypes-in-patients-with-chronic-hepatitis-c-virus-infection-in-tianjin-china
#13
Kunyan Qiao, Congdoanh Trieu, Zhixiao Huo, Yanan Du, Wei Hou
BACKGROUND: Two single-nucleotide polymorphisms (SNPs) rs12979860 (C/T) and rs8099917 (T/G), near the interleukin 28B (IL28B, also known as IFN lambda-3, IFNL3) gene, have a strong association with both spontaneous and treatment-induced hepatitis C virus (HCV) clearance. IL28B polymorphisms have shown a marked differential distribution with regional and ethnic variation. The study aimed to investigate the distribution of IL28B rs12979860 and rs8099917 genotypes in patients with chronic hepatitis C (CHC) in Tianjin, China...
April 1, 2018: Clinical Laboratory
https://www.readbyqxmd.com/read/29738637/risk-of-hbv-reactivation-with-direct-acting-antivirals-against-hcv-a-cohort-study-from-egypt-and-meta-analysis-of-published-data
#14
Mohamed El Kassas, Yusuke Shimakawa, Zainab Ali-Eldin, Anna-Louise Funk, Mohamed Naguib Wifi, Samy Zaky, Fathiya El-Raey, Gamal Esmat, Arnaud Fontanet
BACKGROUND & AIMS: Hepatitis B virus (HBV) reactivation in chronic hepatitis C (CHC) patients treated with direct acting antivirals (DAAs) became an issue. However, its frequency has been poorly estimated, due to the varying definitions used and evaluation of heterogeneous study populations, including those concurrently treated for HBV. METHODS: We prospectively followed HBV surface antigen (HBsAg)-positive Egyptians undergoing interferon-free DAAs, to estimate the risk of HBV reactivation and HBV-related hepatitis...
May 8, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29735789/direct-acting-antivirals-improve-hcv-treatment-initiation-and-adherence-among-underserved-african-americans
#15
Kendall R Beck, Nicole J Kim, Mandana Khalili
INTRODUCTION: Adherence to hepatitis C (HCV) care was suboptimal in the interferon era among underserved African Americans (AA), but adherence data in the era of direct acting antivirals (DAA) is lacking in this population. We aimed to evaluate the impact of DAA on HCV care in underserved AA. MATERIAL AND METHODS: Clinical records of AAs undergoing HCV evaluation attending a safety net health system liver clinic were reviewed from 2006 to 2011 (pre-DAA), and January 1, 2014 to December 31, 2016 (post-DAA)...
April 9, 2018: Annals of Hepatology
https://www.readbyqxmd.com/read/29734473/treatment-for-hepatitis-c-virus-associated-mixed-cryoglobulinaemia
#16
REVIEW
Nuria Montero, Alexandre Favà, Eva Rodriguez, Clara Barrios, Josep M Cruzado, Julio Pascual, Maria Jose Soler
BACKGROUND: Hepatitis C virus (HCV)-associated mixed cryoglobulinaemia is the manifestation of an inflammation of small and medium-sized vessels produced by a pathogenic IgM with rheumatoid factor activity generated by an expansion of B-cells. The immune complexes formed precipitate mainly in the skin, joints, kidneys or peripheral nerve fibres. Current therapeutic approaches are aimed at elimination of HCV infection, removal of cryoglobulins and also of the B-cell clonal expansions. The optimal treatment for it has not been established...
May 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29732688/restoration-of-nk-cell-activity-by-interferon-free-daas-combination-therapy-in-chronic-hepatitis-c-patient
#17
Ikuo Nakamura, Yoshihiro Furuichi, Katsutoshi Sugimoto
The interferon-free direct-acting antivirals (DAAs) therapy was one of the effective treatment for chronic hepatitis C (CH(C)) patients. NK activity was reported to be impaired in the patients with HCV. The aim of this study was to examine whether DAAs therapy could restore NK activity in CH(C).
May 6, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29722439/high-efficacy-of-direct-acting-anti-viral-agents-in-hepatitis-c-virus-infected-cirrhotic-patients-with-successfully-treated-hepatocellular-carcinoma
#18
M Persico, A Aglitti, A Aghemo, M Rendina, A Lleo, A Ciancio, V Di Marco, P Lampertico, M R Brunetto, M Zuin, P Andreone, E Villa, G Troshina, V Calvaruso, E Degasperi, B Coco, A Giorgini, F Conti, A Di Leo, L Marzi, V Boccaccio, S Bollani, P Maisonneuve, S Bruno
BACKGROUND: The efficacy of direct-acting anti-viral (DAA) therapy in patients with a history of hepatocellular carcinoma (HCC) is unknown. AIM: We prospectively evaluated whether previously treated HCC affects DAA efficacy in a large real-life cohort of cirrhotic patients. METHODS: From January to December 2015 all consecutive HCV mono-infected patients with cirrhosis and/or history of HCC attending 10 Italian tertiary liver centres were enrolled...
May 3, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29720863/hepatitis-b-and-c-coinfection-in-a-real-life-setting-viral-interactions-and-treatment-issues
#19
Nikolaos Papadopoulos, Maria Papavdi, Anna Pavlidou, Dimitris Konstantinou, Hariklia Kranidioti, George Kontos, John Koskinas, George V Papatheodoridis, Spilios Manolakopoulos, Melanie Deutsch
Background: Only limited data concerning hepatitis B (HBV) and C viruses (HCV) coinfection are available. Direct-acting antivirals (DAAs) may be more effective for HCV clearance than interferon (IFN)-based regimens with a risk of HBV reactivation. Methods: We retrospectively enrolled 40 HBV/HCV-coinfected patients to evaluate their clinical profile and treatment outcomes. Results: Chronic dual infection was present in 25/40 (62.5%) patients, acute HCV superinfection in 5/40 (12...
May 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29708289/safety-and-efficacy-of-hcv-eradication-during-etanercept-treatment-for-severe-psoriasis
#20
Leonardo Pescitelli, Linda Lazzeri, Lara Tripo, Federica Ricceri, Antonella Di Cesare, Francesca Prignano
Treatment of severe psoriasis in HCV positive patients is challenging, because several psoriasis medications have a toxic effect on the liver, and interferon alpha, used to treat hepatitis, can induce worsening of psoriatic lesions. TNF-alpha inhibitors seem to be a safe and effective option in HCV positive psoriatic patients, but there are concerns about long-term safety, impact on liver fibrosis progression and risk of immune-mediated liver injury. With regard to HCV treatment, new direct-acting antiviral therapies (DAA) seem to be extremely effective, with minimal side effects, but little is known about possible interactions with other medications, particularly with biologics...
April 30, 2018: Dermatologic Therapy
keyword
keyword
58041
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"